Advertisement
Product › Details
STP938 (Step Pharma)
Next higher product group | CTPS1 inhibitor | |
Status | 2021-03-24 development pp existent | |
Organisation | Step Pharma SAS | |
Step Pharma SAS. (3/24/21). "Press Release: Step Pharma Raises EUR35 Million in Series B Financing to Advance First in Class CTPS1 inhibitor into the Clinic in T Cell Malignancies". Archamps.
Step Pharma, a biotech company developing novel drugs for oncology and autoimmune diseases, today announced the successful closing of a EUR35 million Series B financing. New investors Hadean Ventures and Sunstone Life Science Ventures co-led the round, joining existing investors Kurma Partners, Pontifax and Bpifrance, who reinvested through its Innovative Biotherapies and Rare Diseases fund and InnoBio 2 fund. As part of the financing, Jacob L Moresco from Sunstone Life Science Ventures and Walter Stockinger from Hadean Ventures will join the Step Pharma Board of Directors.
The proceeds will be used to advance Step Pharma’s lead proprietary CTPS1 inhibitor, STP938, into clinical development for the treatment of T-cell malignancies. In addition, Step Pharma will use the funding to advance development of CTPS1 inhibitors in other haematological malignancies and solid tumours. CTPS1 (cytidine triphosphate synthase 1) is an enzyme that plays a critical role in DNA synthesis, cell division and proliferation but whose function is highly selective to certain cell types, in particular proliferating T cells, making it an ideal target for drug development.
Roger Franklin, Partner at Hadean Ventures said: “CTPS1 is an elegant target for the development of drugs in the T-cell malignancy space in which there is significant unmet need. The strength of the underlying science, its support from human genetic work as well as the clear commercial opportunity were key factors in our decision to back Step and co-lead this significant financing. We very much look forward to working with the great team at Step as this exciting programme moves into the clinic.”
“Step Pharma is a clear leader in CTPS1 research. They have made significant progress in advancing their 1st in class selective CTPS1 inhibitors toward clinical development and expanding the potential therapeutic applications,” added Jacob L Moresco from Sunstone Life Science Ventures
“The closing of this Series B will enable Step Pharma to transform into a clinical-stage company, enabling us to advance our lead compound into the clinic in Q1 2022,” said Andrew Parker, CEO of Step Pharma. “We’d like to welcome our new investors and thank existing investors for their continued support of the company.”
Targeting CTPS1
Cytidine nucleotide triphosphate (CTP) is a precursor required for DNA synthesis and cell division. Patients deficient in the enzyme CTPS1 have an altered immune cell proliferation response to immune challenge but no other deleterious effects. This same pathway supports the uncontrolled growth of cancerous T and B cells, thus inhibiting CTPS1 represents a novel precision oncology approach to specifically block proliferation and induce killing of cancerous cells in lymphoma and leukemia.
About Step Pharma
Step Pharma is focused on the development of a novel class of oral nucleotide synthesis inhibitors targeting CTPS1 for the improved treatment of a range of oncology and autoimmune diseases. The company has identified several inhibitors of CTPS1, with the most advanced, STP938 being prepared for clinical studies in T-cell malignancies.
Step Pharma was founded in June 2014 by Kurma Partners, the Imagine Institute, and Sygnature Discovery based on the scientific discoveries of Prof. Alain Fischer and Dr Sylvain Latour’s laboratory at the Imagine Institute, Paris. Step Pharma is based in Archamps, France. More information on the company can be found at www.step-ph.com.
Contacts:
Step Pharma
Andrew Parker
info@step-ph.com
Tel: +33 (0) 7 81 54 80 61
Halsin Partners
Mike Sinclair
msinclair@halsin.com
Tel: +44 (0) 207 318 2955
Record changed: 2023-07-10 |
Advertisement
More documents for cancer drug
- [1] Theolytics Ltd.. (4/17/24). "Press Release: Theolytics Successfully Closes Latest Financing Raising Total of £19M ($24.5M) and Welcomes Sound Bioventures as New Investor". Oxford....
- [2] Genmab A/S. (4/3/24). "Press Release: Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio". Copenhagen & Seattle, WA....
- [3] Angelini Ventures S.p.A.. (3/21/24). "Press Release: Angelini Ventures Invests into Extended €75.8 Million ($82 Mmillion) Series C Financing Round for Nouscom". Rome....
- [4] Tubulis GmbH. (3/14/24). "Press Release: Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline". Munich....
- [5] Eckert & Ziegler AG. (1/8/24). "Press Release: Eckert & Ziegler and ArtBio Announce Manufacturing and Supply Partnership for Lead-212 Conjugates". Berlin & Cambridge, MA....
- [6] Merck KGaA. (1/4/24). "Press Release: Merck Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna [Not intended for UK-, US- or Canada-based media]". Darmstadt....
- [7] Simris Group AB. (12/20/23). "Press Release: Simris Biologics Signs Material Transfer Agreement with Pre-clinical Biotech Company to Develop Linker-Payloads"....
- [8] Lundbeckfonden. (10/16/23). "Press Release: Venture Forces Invest Millions in New Type of Treatment for Particularly Aggressive Form of Cancer"....
- [9] IO Biotech, Inc.. (8/7/23). "Press Release: IO Biotech, Inc. Announces $75 Million Private Placement Financing". New York, NY....
- [10] Accession Therapeutics Ltd.. (7/19/23). "Press Release: Chief Business Officer Appointed at Accession Therapeutics as Company Prepares for Clinical Trials". Oxford....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top